IRIS

Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.

Centonze, D., Furlan, R., Gasperini, C., Salvetti, M., Battistini, L. (2008). Early relapses after the first dose of natalizumab in active multiple sclerosis patients. MULTIPLE SCLEROSIS, 14(8), 1137-1138 [10.1177/1352458508092810].

Early relapses after the first dose of natalizumab in active multiple sclerosis patients

CENTONZE, DIEGO;
2008-09-01

Abstract

Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.
set-2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Recurrence; Male; Time Factors; Young Adult; Female; Multiple Sclerosis; Antibodies, Monoclonal; Adult; Humans
Centonze, D., Furlan, R., Gasperini, C., Salvetti, M., Battistini, L. (2008). Early relapses after the first dose of natalizumab in active multiple sclerosis patients. MULTIPLE SCLEROSIS, 14(8), 1137-1138 [10.1177/1352458508092810].
Centonze, D; Furlan, R; Gasperini, C; Salvetti, M; Battistini, L
Articolo su rivista
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/41484
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact